An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. A shift to a preventative approach is necessary for the efficiency and sustainability of our healthcare systems. Central to this shift is the often-underutilized tool of life-course immunization.
Unidos En Salud organisers have now provided COVID-19 testing to 14,000 people, targeting Latinx workers - one of the most hard-hit communities in San Francisco.
While long COVID is slowly becoming more understood, ordinary COVID-19 patients are experiencing lasting effects - scientists discovered that 76% of people have atleast one recurring symptom, six months after the original illness.
The approval of the Moderna COVID vaccine in the UK comes 2 days after European medical regulators, but not a moment too soon - the death toll continues to climb, standing at 78,508 currently.
With rising COVID-19 cases, secondary schools will officially remain shut until 18 January - but primary schools across the country have also decided to stay closed.
As of midnight tonight (20 December), London and the South East will enter strict Tier 4 restrictions - which includes no household mixing over Christmas, and no commuting to work.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
The independent experts of the FDA say the Pfizer vaccine is good to go, which means that the COVID vaccine should be formally approved in a matter of days.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Pfizer/BioNTech COVID-19 vaccine for use in the UK and will be made available as early as next week.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
